Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

The pharmaceutical market consists of sales of pharmaceuticals and related services by entities (organizations, sole traders, and partnerships) that produce pharmaceuticals used in treating diseases such as diabetes, cancer, cardiovascular disease, chronic kidney diseases, and others. Pharmaceuticals can be any type of drugs that are used for medicinal purposes, in the treatment of diseases . This industry includes organizations or companies that produce biologics and pharmaceutical drugs. Pharmaceutical companies are offering drugs for customized individual treatment for various diseases as listed above. Personalized medicine, also referred to as precision medicine, aims to provide medical care according to the patient's individual characteristics and genetic makeup. Precision therapies are increasingly being adopted as firms increasingly let go of the one-size-fits-all model for common medical conditions such as lung cancer, melanoma (skin cancer), colon cancer, and pancreatic cancer. It can also help with some rare childhood illnesses, cystic fibrosis, and HIV.

The India & Oman pharmaceutical industry market is estimated to be valued at US$ 47,179.5 million in 2021 and is expected to exhibit a CAGR of 12.7% over the forecast period (2021-2030).

Figure 1. India & Oman Pharmaceutical Industry Market Share (%) in Terms of Value, By Country, 2021

India & Oman Pharmaceutical Industry  | Coherent Market Insights

Increasing number of product launches in the India pharmaceutical industry is expected to drive the market growth over the forecast period.

The increasing number of product launches in the India pharmaceutical industry is expected to drive growth of the India pharmaceutical industry market over the forecast period. For instance, in February 2021, Glenmark Pharmaceuticals, a pharmaceutical company in India, announced the launch of SUTIB, a generic version of Sunitinib oral capsules indicated for the treatment of kidney cancer in India.

request-sample

India & Oman Pharmaceutical Industry Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 47,179.5 Mn
Historical Data for: 2011 to 2020 Forecast Period: 2021 to 2030
Forecast Period 2021 to 2030 CAGR: 12.7% 2030 Value Projection: US$ 138,308.1 Mn
Geographies covered:
  • India and Oman
Segments covered:
  • By Drug: Generic, Patented (Branded)
  • By Type: Prescription Drugs, Over the Counter Drugs
  • By Drug Class: Analgesics, Anesthetics, Antibacterials, Antidepressants, Corticosteroids, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Anticonvulsants, Antivirals, Anticoagulants, ACE inhibitors, Hormonal agents, Insulin, Contraceptives, Diuretics, Vaccines, Others
  • By Application: Cardiovascular (Ischemic Heart Disease, Others), Hypertension, Musculoskeletal, Oncology, Anti-infective, Cirrhosis, Metabolic Disorder(Diabetes, Others), Weight Management, Central Nervous System, Genito-urinary, Kidney Disease, Gastrointestinal, Respiratory, Hematology, Dermatology, Ophthalmology, Others (Nutraceutical, Dentals, and Gynecology)
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Pfizer, Inc., Bristol Myers Squibb, Sanofi S.A., F. Hoffmann-La Roche AG, Bayer AG, Novartis International AG, Merck & Co., Inc., AbbVie, GlaxoSmithKline plc, Eli Lilly and Company, Zydus Cadila, Aurobindo Pharma Ltd., Cipla Ltd., Dr. Reddy's Laboratories Ltd., Lupin Ltd., Sun Pharmaceutical Industries Limited, Serum Institute of India Pvt. Ltd., Biocon Limited, Strides Pharma Science Limited, and Unichem Laboratories

Growth Drivers:
  • Increasing number of product launches in the pharmaceutical industry
  • Rising government initiatives in the pharmaceutical industry
  • Increasing prevalence of chronic diseases
Restraints & Challenges:
  • High number of banned products
  • Campaigns against spurious drugs 
  • Lack of national health insurance plan 
  • Product recall  due to non-conformity to the stability specifications

Figure 2. India & Oman Pharmaceutical Industry Market Share (%), by Drug, 2020

India & Oman Pharmaceutical Industry  | Coherent Market Insights

The increasing prevalence of chronic diseases in Oman is expected to drive the market growth over the forecast period.

For instance, according to The Ministry of Health (MOH) report 2017, the number of recorded tumor cases in 2017 reached 2,101 including 1,892 (90.05%) cases among Omanis, 188 (8.95%) cases among residents, and 19 (0.9%) cases of Carcinoma in situ among Omanis. Furthermore, according to the similar source, the number of cancer cases among Omani males reached 887 (46.9%) compared to 1,005 (53.1%) cases among Omani females. 127 (6.7%) cases were registered among Omani children at the age of 14 and under in 2017.

India & Oman Pharmaceutical Industry market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency in 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, the number of COVID-19 cases reported in India as of July 8, 2021 are approximately 30,663,665 confirmed cases and 404,211 deaths. Moreover, according to the same source, the number of COVID-19 cases reported in Oman as of July 8, 2021 are approximately 278,560 confirmed cases of COVID-19 and 3,339 deaths. The major challenges faced by key players include supply of raw materials required for manufacturing instruments and reagent kits due to irregularities in transportation facility, irregular demand for products from the retailers due to increasing number of patients suffering from COVID-19 and other life threatening disorders.

Thus, to overcome the dependency of active pharmaceutical ingredient (API) and raw materials, the Indian government is focused on developing and manufacturing of raw materials and active pharmaceutical ingredients. For instance, in 2020, the government of India announced the incentive package of INR 13.76 billion (US$ 18.39 Bn) for the promotion of domestic manufacturing of critical key starting materials, drug intermediates, APIs, and medical devices in India. Moreover, according to the Directorate-General of Pharmacy and Drug Control Oman 2020, in Oman there was prohibition on the export of masks, hand sanitizers, and medical supply products to the other countries due to shortage of the pharmaceutical appliances and products in Oman.

India & Oman Pharmaceutical Industry Market: Restraint

High number of banned products in India and lack of national health insurance plan in Oman are expected to hinder growth of the India & Oman pharmaceutical industry market. For instance, according to the Central Drugs Standard Control Organization and Directorate General of Health Services Ministry of Health & Family Welfare Government of India, banned drugs in 2018 include combinations of Nimesulide + Levocetrizine, Ofloxacin + Ornidazole Injection and Glucosamine + Ibuprofen due to their side effects and drug abuse situations. Whereas, lack of national health insurance plan in Oman leads to the expenses of the public healthcare system to be depended on the government, perpetuating reliance on state provisions and straining the government budget and is expected to hinder the growth of the market.

Key Players

Major players operating in the India & Oman pharmaceutical industry market include Pfizer, Inc., Bristol Myers Squibb, Sanofi S.A., F. Hoffmann-La Roche AG, Bayer AG, Novartis International AG, Merck & Co., Inc., AbbVie, GlaxoSmithKline plc, Eli Lilly and Company, Zydus Cadila, Aurobindo Pharma Ltd., Cipla Ltd., Dr. Reddy's Laboratories Ltd., Lupin Ltd., Sun Pharmaceutical Industries Limited, Serum Institute, Biocon Limited, Strides Pharma Science Limited, and Unichem Laboratories

The pharmaceutical industry is responsible for the research, development, production, and distribution of medications. The pharmaceutical industry is undergoing a consolidation phase in order to combat price pressure, competition, and patent cliffs. Innovation is of vital importance for steady growth of key market players. They have been mainly dependent on a few blockbuster molecules. The patent expiry of blockbuster drugs is expected to pave way for generics. Due to difference in genetic composition of varied individuals, innovation is becoming more complex. This is influencing players offering complementary products and services to collaborate for new product development. Moreover, key market players are investing in consumer health products, with increasing consumer’s health awareness and emerging trend of self-medication. These trends are encouraging the key market players to enter the OTC market and leverage their brand equity among the doctors, chemists, and consumers.

Market Dynamics

The increasing prevalence of chronic diseases such as diabetes, cancer, cardiovascular disease, chronic kidney diseases, and others is expected to drive the growth of Oman pharmaceutical industry market over the forecast period. For instance, according to the World Health Organization 2018 report, in 2018, coronary heart disease deaths in Oman reached 2,904 or 28.23% of total deaths. The age adjusted death rate is 179.48 per 100,000 population, which ranks Oman at 45th position in the world in coronary heart disease patient population. Moreover, according to the World Health Organization (WHO), chronic kidney disease (CKD) is the sixth main cause of death in Oman, with a rate of 18.10 per 100,000 population (2.97% of total deaths) every year caused due to CKD in Oman. Similarly, Oman was ranked 51st among the top world countries in which CKD is a major cause of death.

Key features of the study:

  • This report provides in-depth analysis of the India & Oman pharmaceutical industry market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2021–2030), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the India & Oman pharmaceutical industry market based on the following parameters – company highlights, types portfolio, key highlights, financial performance, and market strategies
  • Key companies covered as a part of this study include Pfizer, Inc., Bristol Myers Squibb, Sanofi S.A., F. Hoffmann-La Roche AG, Bayer AG, Novartis International AG, Merck & Co., Inc., AbbVie, GlaxoSmithKline plc, Eli Lilly and Company, Zydus Cadila, Aurobindo Pharma Ltd., Cipla Ltd., Dr. Reddy's Laboratories Ltd., Lupin Ltd., Sun Pharmaceutical Industries Limited, Serum Institute of India Pvt. Ltd., Biocon Limited, Strides Pharma Science Limited, and Unichem Laboratories
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The India & Oman pharmaceutical industry market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the India & Oman pharmaceutical industry market

Detailed Segmentation:

  • India & Oman Pharmaceutical Industry Market, By Drug:
    • Generic
    • Patented (Branded)
  • India & Oman Pharmaceutical Industry Market, By Type:
    • Prescription Drugs
    • Over the Counter Drugs
  • India & Oman Pharmaceutical Industry Market, By Drug Class:
    • Analgesics
    • Anesthetics
    • Antibacterials
    • Antidepressants
    • Corticosteroids
    • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • Anticonvulsants
    • Antivirals
    • Anticoagulants
    • ACE inhibitors
    • Hormonal agents
    • Insulin
    • Contraceptives
    • Diuretics
    • Vaccines
    • Others
  • India & Oman Pharmaceutical Industry Market, By Application:
    • Cardiovascular
      • Ischemic Heart Disease
      • Others
    • Hypertension
    • Musculoskeletal
    • Oncology
    • Anti-infective
    • Cirrhosis
    • Metabolic Disorder
      • Diabetes
      • Others
    • Weight Management
    • Central Nervous System
    • Genito-urinary
    • Kidney Disease
    • Gastrointestinal
    • Respiratory
    • Hematology
    • Dermatology
    • Ophthalmology
    • Others (Nutraceutical, Dentals, and Gynecology)
  • India & Oman Pharmaceutical Industry Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • India & Oman Pharmaceutical Industry Market, By Country:
    • India
    • Oman
  • Company Profiles
    • Pfizer, Inc.
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • SWOT Analysis
      • Strategies
    • Bristol Myers Squibb
    • Sanofi S.A.
    • Hoffmann-La Roche AG
    • Bayer AG
    • Novartis International AG
    • Merck & Co., Inc.
    • AbbVie Inc.
    • GlaxoSmithKline plc.
    • Eli Lilly and Company
    • Zydus Cadila
    • Aurobindo Pharma Ltd.
    • Cipla Ltd.
    • Reddy's Laboratories Ltd.
    • Lupin Ltd.
    • Sun Pharmaceutical Industries Limited
    • Serum Institute of India Pvt. Ltd.
    • Biocon Limited
    • Strides Pharma Science Limited
    • Unichem Laboratories

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Drug
      • Market Snapshot, By Type
      • Market Snapshot, By Drug Class
      • Market Snapshot, By Application
      • Market Snapshot, By Distribution Channel
      • Market Snapshot, By Country
      • Market Opportunity Map
  3. India & Oman Pharmaceutical Industry Market
    • Analysis of the Indian Pharmaceutical Industry
      • Drivers & Restraints
      • Market Opportunity
      • Market Trends
      • Impact Analysis
      • Mergers and Acquisitions
      • Epidemiology
      • PEST Analysis
      • SWOT Analysis
      • Regulatory Scenario
      • Reimbursement Scenario
      • Major Indian Exporters/Manufacturers (Global)
      • Major Indian Importers
      • Major Indian Exporters/Manufacturers (To Oman)
      • Indian Pharmaceutical Drugs Import Market
      • Indian Pharmaceutical Drugs Export Market
        • Indian Pharmaceutical Drugs Export to Oman Market
    • Analysis of the Oman Pharmaceutical Industry
      • Drivers & Restraints
      • Market Opportunity
      • Market Trends
      • Impact Analysis
      • Mergers and Acquisitions
      • Epidemiology
      • PEST Analysis
      • SWOT Analysis
      • Regulatory Scenario
      • Industry Regulations
        • Trade Regulations and Procedures For Export to Oman
        • Trade Barriers (Tariff, Non-tariff, etc.) and Other Entry-level Barriers for Indian Pharma Products in Oman
      • Reimbursement Scenario
      • Major Oman Exporters/Manufacturers (Global)
      • Major Oman Importers
      • Strategy For Indian Pharma Products In Oman
      • India's Strategy For Effectively Entering Oman Pharma Market
      • USP Of Indian Companies In The Oman Pharmaceutical Market And Positioning Strategy
      • Oman Pharmaceutical Drugs Import Market
      • Oman Pharmaceutical Drugs Export Market
        • Oman Pharmaceutical Drugs Export to India Market
      • Ayurvedic Drugs Market
        • Overview of Indian Ayurvedic Drugs
        • Ayurvedic Products by Indian Companies With Certification of Pharmaceutical Product (COPP) Granted As Per WHO-GMP Certification Scheme (1/2)
        • Overview of Oman Ayurvedic Drugs Import
        • Indian Ayurvedic Companies Registered in Oman
      • Strategies Adopted By Local Oman Manufacturers
  4. India & Oman Pharmaceutical Industry Market - Impact of Coronavirus (Covid-19) Pandemic
    • Economic Impact
    • Impact of COVID-19 on Pharmaceutical Market
    • Demand and Supply Chain Analysis
    • Government Initiative
  5. India & Oman Pharmaceutical Industry Market, By Drug, 2011 – 2030 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2030 (%)
      • Y-o-Y Growth Analysis, 2012 – 2030
      • Segment Trends
    • Generic
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
    • Patented (Branded)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
  6. India & Oman Pharmaceutical Industry Market, By Type, 2011 – 2030 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2030 (%)
      • Y-o-Y Growth Analysis, 2012 – 2030
      • Segment Trends
    • Prescription Drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
    • Over the Counter Drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million
  7. India & Oman Pharmaceutical Industry Market, By Drug Class, 2011 – 2030 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2030 (%)
      • Y-o-Y Growth Analysis, 2012 – 2030
      • Segment Trends
    • Analgesics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
    • Anesthetics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
    • Antibacterials
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
    • Antidepressants
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
    • Corticosteroids
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
    • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
    • Anticonvulsants
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
    • Antivirals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
    • Anticoagulants
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
    • ACE inhibitors
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
    • Hormonal agents
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
    • Insulin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
    • Contraceptives
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
    • Diuretics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
    • Vaccines
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
  8. India & Oman Pharmaceutical Industry Market, By Application, 2011 – 2030 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2030 (%)
      • Y-o-Y Growth Analysis, 2012 – 2030
      • Segment Trends
    • Cardiovascular
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
      • Ischemic Heart Disease
      • Others
    • Hypertension
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
    • Musculoskeletal
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
    • Oncology
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
    • Anti-infective
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
    • Metabolic Disorder
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
      • Diabetes
      • Others
    • Weight Management
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
    • Central Nervous System
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
    • Genito-urinary
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
    • Kidney Disease
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
    • Gastrointestinal
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
    • Respiratory
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
    • Hematology
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
    • Dermatology
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
    • Ophthalmology
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
    • Others (Nutraceutical, Dentals, and Gynecology)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
  9. India & Oman Pharmaceutical Industry Market, By Distribution Channel, 2011 – 2030 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2030 (%)
      • Y-o-Y Growth Analysis, 2012 – 2030
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2011 – 2030 (US$ Million)
  10. India & Oman Pharmaceutical Industry Market, By Country, 2011 – 2030 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2030 (%)
      • Y-o-Y Growth Analysis, 2012 – 2030
      • Regional Trends
    • India
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2011 – 2030 (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Type, 2011 – 2030 (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2011 – 2030 (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Application, 2011 – 2030 (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2011 – 2030 (US$ Million)
    • Oman
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2011 – 2030 (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Type, 2011 – 2030 (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2011 – 2030 (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Application, 2011 – 2030 (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2011 – 2030 (US$ Million)
  11. Case Study of Successful Foreign Pharma Product Entries Into    Oman Market
    • Case Study of 5 Successful Foreign Pharma Companies Entry Into Oman Market
    • Company Profiles (Global)
      • Pfizer, Inc.
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • SWOT Analysis
        • Strategies
      • Bristol-Myers Squibb Company
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • SWOT Analysis
        • Strategies
      • Sanofi S.A.
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • SWOT Analysis
        • Strategies
      • F. Hoffmann-La Roche AG
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • SWOT Analysis
        • Strategies
      • Bayer AG
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • SWOT Analysis
        • Strategies
      • Novartis International AG
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • SWOT Analysis
        • Strategies
      • Merck & Co., Inc.
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • SWOT Analysis
        • Strategies
      • AbbVie Inc.
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • SWOT Analysis
        • Strategies
      • GlaxoSmithKline plc.
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • SWOT Analysis
        • Strategies
      • Eli Lilly and Company
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • SWOT Analysis
        • Strategies
    • Company Profiles (India)
      • Zydus Cadila
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • SWOT Analysis
        • Strategies
      • Aurobindo Pharma Ltd.
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • SWOT Analysis
        • Strategies
      • Cipla Inc.
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • SWOT Analysis
        • Strategies
      • Dr. Reddy's Laboratories Ltd.
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • SWOT Analysis
        • Strategies
      • Lupin Ltd.
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • SWOT Analysis
        • Strategies
      • Sun Pharmaceutical Industries Limited
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • SWOT Analysis
        • Strategies
      • Serum Institute of India Pvt. Ltd.
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • SWOT Analysis
        • Strategies
      • Biocon Limited
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • SWOT Analysis
        • Strategies
      • Strides Pharma Science Limited
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • SWOT Analysis
        • Strategies
      • Unichem Laboratories Limited
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • SWOT Analysis
        • Strategies
  12. Section
    • Research Methodology
    • About us

*Browse 89 market data tables and 64 figures on "India & Oman Pharmaceutical Industry Market” – India & Oman forecast to 2030

FAQgrowicon

Frequently Asked Questions

The India & Oman pharmaceutical industry market size is estimated to be valued at US$ 47,179.5 million in 2021 and is expected to exhibit a CAGR of 12.7% between 2021 and 2030.
Increasing number of product launches in the pharmaceutical industry, rising government initiatives in the pharmaceutical industry in India, and increasing prevalence of chronic diseases in Oman are expected to drive the market growth over the forecast period.
Generics drug is the leading segment in the market.
High number of banned products, campaigns against spurious drugs in India, and lack of national health insurance plan and product recall in Oman the major factor restraining growth of the market.
Major players operating in the market include Pfizer, Inc., Bristol Myers Squibb, Sanofi S.A., F. Hoffmann-La Roche AG, Bayer AG, Novartis International AG, Merck & Co., Inc., AbbVie, GlaxoSmithKline plc, Eli Lilly and Company, Zydus Cadila, Aurobindo Pharma Ltd., Cipla Ltd., Dr. Reddy's Laboratories Ltd., Lupin Ltd., Sun Pharmaceutical Industries Limited, Serum Institute of India Pvt. Ltd., Biocon Limited, Strides Pharma Science Limited, and Unichem Laboratories
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.